6 research outputs found
Promises of the past : a discontinuous history of art in former Eastern Europe /
No full textCatalog of an exhibition, in co-edition with Centre Pompidou, Paris, Galerie Sud and Espace 315, 14 April - 14 July 2010. Head curators: Christine Macel & Joanna MytkowskaIncludes bibliographical references and index.Promises of the past / Christine Macel & Joanna Mytkowska -- On potential histories, discontinuity and politics of desire / Elena Filipovic ... [et al.] -- The post-bipolar order and the status of public and private under communism / Vit Havranek -- Not so elsewhere / Jan Verwoert -- Catalogue "Promisses of the Past" (Galerie Sud) : Monika Sosnowska, Tobias Putrih, Marina Abramovic, Pawel Althamer, Yael Bartana, Maria Bartuszova, Cezary Bodzianowski, Mircea Cantor, Attila Csorgo, Tacita Dean, Braco Dimitrijevic, Thea Djordjadze, Miklos Erdely, Stano Filko, Cyprien Gaillard, Gorgona, Tomislav Gotovac, Ion Grigorescu, Tibor Hajas, Sanja Ivekovic, Daniel Knorr, Julius Koller, Jiri Kovanda, Edward Krasinski, David Maljkovic & Vojin Bakic, Mangelos, Ciprian Muresan, Roman Ondak, Nesa Paripovic, Ewa Partum, Dan Perjovschi, Marjetica Potrc, Dimitri Prigov, Katerina Seda, Mladen Stilinovic, Alina Szapocznikow, Tamas Szentjoby, Balint Szombathy, Endre Tot, Goran Trbuljak, Alexander Ugay, Tirana Case / Olafur Eliasson ... [et al.] -- Catalogue "Sources, archives, documents and films" (Espace 315) / text by Natasa Petresin-Bachelez -- A winding road / Jindrich Chalupecky -- The Leninist utopia / Slavoj Zizek -- The (former) East and its identity / Igor Zabel -- On the spatial turn / Piotr Piotrowski -- Nostalgia, ruinophilia and the "off-modern" history / Svetlana Boym -- The way of the shovel : on the archaeological imaginary in art / Dieter Roelstraete -- Interrupted histories / Zdenka Badovinac -- What do archives forget? : memory and histories, from the archive of Kwiekulik / Luiza Nader -- "We are all autodidacts" : what, how & for whom
Evaluation of predictive value of 1H MR spectroscopy for response of neoadjuvant chemotherapy in musculoskeletal tumors
No full textPURPOSE: Bone and soft tissue tumors are rare. There is a variety of types and each one has its own particular behavior, treatment and patient outcome. The assessment of treatment response following the 3rd cycle of chemotherapy is one of the most important aspects of patient care, as therapeutic options and the timing of surgery may vary depending on the achievement of response. Hence, we focused on the advanced imaging technique, proton magnetic resonance spectroscopy (1H MRS), aiming at improving the diagnostic accuracy and the tumor response to therapy, based on the absolute concentration of choline (Cho) as biomarker of malignancy.
METHODS: Twenty patients were studied. All of them had a pathological diagnosis after biopsy. MRI examinations were performed using a 1.5 T MR scanner (Avanto; Siemens, Erlangen, Germany). Single-voxel 1H MR spectroscopy was performed by using a PRESS with TR/TE 1530/100 ms, before chemotherapy and after the 3rd cycle. 1H MRS was processed in LCmodel.
RESULTS: Of 20 patients, 7 responded to neoadjuvant chemotherapy and 13 did not. In responders, the mean concentration of tCho before therapy was 4.7±2.5 mmol/kg, which showed statistically significant reduction after therapy. In non-responders, the mean tCho concentration before therapy was 2.9±0.9 mmol/kg which remained the same or increased after the 3rd cycle of neoadjuvant chemotherapy (2.7±2.5 mmol/kg; range from 2.05 to 5.79 with no statistical significance). Compared to reference healthy group, tCho concentrations were increased in all cases
Association of serum soluble urokinase receptor levels with progression of kidney disease in children
No full textPubMedID: 28873129IMPORTANCE: Conventional methods to diagnose and monitor chronic kidney disease (CKD) in children, such as creatinine level and cystatin C–derived estimated glomerular filtration rate (eGFR) and assessment of proteinuria in spot or timed urine samples, are of limited value in identifying patients at risk of progressive kidney function loss. Serum soluble urokinase receptor (suPAR) levels strongly predict incident CKD stage 3 in adults. OBJECTIVE: To determine whether elevated suPAR levels are associated with renal disease progression in children with CKD. DESIGN, SETTING, AND PARTICIPANTS: Post hoc analysis of 2 prospectively followed up pediatric CKD cohorts, ie, the ESCAPE Trial (1999-2007) and the 4C Study (2010-2016), with serum suPAR level measured at enrollment and longitudinal eGFR measured prospectively. In the 2 trials, a total of 898 children were observed at 30 (ESCAPE Trial; n = 256) and 55 (4C Study; n = 642) tertiary care hospitals in 13 European countries. Renal diagnoses included congenital anomalies of the kidneys and urinary tract (n = 637 [70.9%]), tubulointerstitial nephropathies (n = 92 [10.2%]), glomerulopathies (n = 69 [7.7%]), postischemic CKD (n = 42 [4.7%]), and other CKD (n = 58 [6.5%]). Total follow-up duration was up to 7.9 years, and median follow-up was 3.1 years. Analyses were conducted from October 2016 to December 2016. EXPOSURES: Serum suPAR level was measured at enrollment, and eGFR was measured every 2 months in the ESCAPE Trial and every 6 months in the 4C Study. The primary end point of CKD progression was a composite of 50% eGFR loss, eGFR less than 10 mL/min/1.73 m2, or initiation of renal replacement therapy. MAIN OUTCOMES AND MEASURES: The primary end point in this study was renal survival, defined as a composite of 50% loss of GFR that persisted for at least 1 month, the start of renal replacement therapy, or an eGFR less than 10 mL/min/1.73 m2. RESULTS: Of the 898 included children, 560 (62.4%) were male, and the mean (SD) patient age at enrollment was 11.9 (3.5) years. The mean (SD) eGFR was 34 (16) mL/min/1.73 m2. The 5-year end point–free renal survival was 64.5% (95% CI, 57.4-71.7) in children with suPAR levels in the lowest quartile compared with 35.9% (95% CI, 28.7-43.0) in those in the highest quartile (P < .001). By multivariable analysis, the risk of attaining the end point was higher in children with glomerulopathies and increased with age, blood pressure, proteinuria, and lower eGFR at baseline. In patients with baseline eGFR greater than 40 mL/min/1.73 m2, higher log-transformed suPAR levels were associated with a higher risk of CKD progression after adjustment for traditional risk factors (hazard ratio, 5.12; 95% CI, 1.56-16.7; P = .007). CONCLUSIONS AND RELEVANCE: Patients with high suPAR levels were more likely to have progression of their kidney disease. Further studies should determine whether suPAR levels can identify children at risk for future CKD. © 2017 American Medical Association. All rights reserved.Fifth Framework Programme: QLRT-2001-00908 Boehringer Ingelheim National Institute of Diabetes and Digestive and Kidney Diseases: R01DK100307 Baxter International Seventh Framework Programme 01EO0802, R01DK101350Accepted for Publication: July 6, 2017. Correction: This article was corrected on October 9, 2017, to fix an error in the presentation of data in Table 1. Published Online: September 5, 2017. doi:10.1001/jamapediatrics.2017.2914 Author Affiliations: Center for Pediatrics and Adolescent Medicine, University Hospital Heidelberg, Heidelberg,Germany(Schaefer,Wühl);Departmentof Pediatrics, Division of Nephrology, New York University Langone Medical Center, New York (Trachtman); Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany (Kirchner); Emory Clinical Cardiovascular Research Institute, Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia (Hayek);DepartmentofPediatricNephrology,Faculty of Medicine, Cukurova University, Adana, Turkey (Anarat);PediatricNephrology,HacettepeUniversity Faculty of Medicine, Ankara, Turkey (Duzova); Pediatric Nephrology, Ege University Faculty of Medicine, Izmir, Turkey (Mir); University Children’s Hospital Belgrade, Belgrade, Serbia (Paripovic); DepartmentofPediatricNephrology,IstanbulMedical Faculty,Istanbul,Turkey(Yilmaz);PediatricNephrology, Giannina Gasline Institute, Genova, Italy (Lugani); Pediatric Nephrology, Vienna University Children’s Hospital, Vienna, Austria (Arbeiter); Nephrology, KidneyTransplantationandHypertension,Children’s Memorial Health Institute, Warzaw, Poland (Litwin); Pediatric Nephrology, Children’s Hospital, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (Oh); Division of Pediatric Nephrology, Bambino Gesù Children’s Hospital and Research Institute,Rome,Italy(Matteucci);PediatricNephrology, Charité Children’s Hospital, Berlin, Germany (Gellermann); Children’s Dialysis Center, Hospital St Georg, Leipzig, Germany (Wygoda); Vilnius University, Pediatric Center, Vilnius, Lithuania (Jankauskiene); KfH Kidney Center for Children, Marburg, Germany (Klaus); Pediatrics, University Hospital Motol, Prague, Czech Republic (Dusek); Pediatric Nephrology and Dialysis, Fondazione OSP MaggiorePoliclinico,Milano,Italy(Testa);Department of Pediatric and Adolescent Nephrology, Medical University Gdansk, Gdansk, Poland (Zurowska); Pediatrics,HospitalSãoJoão,Porto,Portugal(Caldas Afonso); Department of Medicine, Rush University Medical Center, Chicago, Illinois (Tracy, Wei, Reiser); Harvard Medical School and Division of Nephrology, MassachusettsGeneralHospital,Charlestown(Sever); The Research Institute at Nationwide Children’s Hospital, The Ohio State University, Columbus (Smoyer). Author Contributions: Drs Schaefer and Kirchner had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Schaefer, Trachtman, Wühl, and Reiser contributed equally to the preparation of this article. Study concept and design: Schaefer, Trachtman, Wühl, Hayek, Anarat, Yilmaz, Lugani, Caldas Afonso, Sever, Smoyer. Acquisition, analysis, or interpretation of data: Schaefer, Trachtman, Wühl, Kirchner, Hayek, Duzova, Mir, Paripovic, Lugani, Arbeiter, Litwin, Oh, Matteucci, Gellermann, Jankauskiene, Klaus, Dusek, Testa, Zurowska, Tracy, Wei, Reiser. Draftingofthemanuscript:Schaefer,Trachtman,Wühl, Kirchner, Hayek, Anarat, Yilmaz, Matteucci, Dusek, Zurowska, Tracy, Wei. Critical revision of the manuscript for important intellectualcontent:Trachtman,Wühl,Kirchner,Hayek, Duzova,Mir,Paripovic,Yilmaz,Lugani,Arbeiter,Litwin, Oh, Gellermann, Jankauskiene, Klaus, Testa, Caldas Afonso, Wei, Sever, Smoyer, Reiser. Statistical analysis: Wühl, Kirchner, Hayek, Matteucci. Obtained funding: Schaefer, Mir, Gellermann. Administrative, technical, or material support: Schaefer, Duzova, Paripovic, Yilmaz, Lugani, Arbeiter, Oh, Klaus, Dusek, Zurowska, Caldas Afonso, Wei, Smoyer, Reiser. Supervision: Schaefer, Lugani, Sever. Conflict of Interest Disclosures: Drs Sever and Reiser are inventors on pending and issued patents related to antiproteinuric therapies. They stand to gain royalties from present and future commercialization. They also are cofounders and advisors to TRISAQ, a biotechnology company. Dr Wei has a pending patent on suPAR in diabetes. He stands to gain royalties from future commercialization products concerning this application. No other conflicts were disclosed. Funding/Support: Dr Schaefer received support for this study from grant agreement 2012-305608 (EURenOmics) from the European Community Seventh Framework Programme (FP7/2007-2013). The ESCAPE Trial was supported by grants from the Boehringer Ingelheim Stiftung, the European Commission Fifth Framework Programme (grant QLRT-2001-00908), the Kuratorium für Dialyse und Nierentransplantation Neu-Isenburg (KfH), and the Baxter Extramural Grant Program. Support for the 4C Study was received from the European Renal Association–European Dialysis and Transplant Association Research Programme, the KfH Foundation for Preventive Medicine, and the German Federal Ministry of Education and Research (grant 01EO0802). Drs Wei, Sever, and Reiser were supported by grant R01DK101350 from the National Institute of Diabetes and Digestive and Kidney Diseases. Dr Trachtman was supported by grant R01DK100307 from the National Institute of Diabetes and Digestive and Kidney Diseases. Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Group Information: The principal investigators of the ESCAPE Trial included the following: Cukurova University School of Medicine, Adana, Turkey: Ali Anarat, MD; Hacettepe University Faculty of Medicine, Ankara, Turkey: Aysin Bakkaloglu, MD, and Fatih Ozaltin, MD; University Children’s Hospital, Belgrade, Serbia: Amira Peco-Antic, MD; Charité Children’s Hospital, Berlin, Germany: Uwe Querfeld, MD, and Jutta Gellermann, MD; First Department o
The relationship between urine heat shock protein 70 and congenital anomalies of the kidney and urinary tract: UTILISE study
No full textBackground: Congenital anomalies of the kidney and urinary tract (CAKUT) are defined as structural malformations of the kidney and/or urinary tract. Heat shock proteins (HSPs) are expressed in the kidney in response to cellular changes, such as thermal, hemodynamic, osmotic, inflammatory, and mechanical stresses. This study aimed to assess uHSP70 levels during acute urinary tract infections (UTI) and non-infection periods in patients with CAKUT, and to evaluate whether uHSP70 is elevated in CAKUT subtypes. Methods: Among patients with CAKUT, 89 patients with UTI (CAKUT-A), 111 without UTI (CAKUT-B), and 74 healthy children were included in the study. uHSP70 levels were measured using enzyme-linked immunosorbent assay (ELISA). Results: uHSP70 level was significantly higher in the CAKUT-A group than in the CAKUT-B and healthy control groups (p 0.05). Conclusion: Urine HSP70 can also be used to predict UTI in patients with CAKUT. Moreover, uHSP70 levels were higher in children with CAKUT during the non-infectious period than in healthy controls. This suggests that children with CAKUT are at risk of chronic non-infectious damage. Copyright © 2024 Aksu, Afonso, Akil, Alpay, Atmis, Aydog, Bakkaloglu, Bayazıt, Bayram, Bilge, Bulut, Cetinkaya, Comak, Demir, Dincel, Donmez, Durmus, Dursun, Dusunsel, Duzova, Ertan, Gedikbasi, Goknar, Guven, Hacihamdioglu, Jankauskiene, Kalyoncu, Kavukcu, Kenan, Kucuk, Kural, Litwin, Montini, Morello, Obrycki, Omer, Misirli Ozdemir, Ozkayin, Paripovic, Pehlivanoglu, Saygili, Schaefer, Schaefer, Sonmez, Tabel, Tas, Tasdemir, Teixeira, Tekcan, Topaloglu, Tulpar, Turkkan, Uysal, Uysalol, Vitkevic, Yavuz, Yel, Yildirim, Yildirim, Yildiz, Yuksel, Yurtseven and Yilmaz.Istanbul Üniversitesi: 29652; Istanbul Üniversitesi; European Society for Paediatric Oncology, SIOPE: 5.2018; European Society for Paediatric Oncology, SIOPEWe gratefully acknowledge that UTILISE was supported by Scientific Research Projects Coordination Unit of Istanbul University, by the European Society for Pediatric Nephrology (ESPN), by the Society for Children’s Kidney Health, and by Istanbul Faculty of Medicine Foundation. We are also very thankful to children participating in this study, our dedicated chemist Orhan Tepeli and diligent students of Istanbul University Istanbul Faculty of Medicine Zeynep Sakur, Sevgi Ipar, Isıl Gul for their great help and assistance.The author(s) declare financial support was received for the research, authorship, and/or publication of this article. UTILISE Study was supported by Scientific Research Projects Coordination Unit of Istanbul University (29652), by the European Society for Pediatric Nephrology (ESPN) (ESPN #5.2018), by the Society for Children’s Kidney Health (1.2018), and by Istanbul Faculty of Medicine Foundation. Acknowledgment
